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Adequate penetration to the infection/colonization site is crucial to attain optimal efficacy of posaconazole against Aspergillus
fumigatus diseases. We evaluated posaconazole exposure in pulmonary epithelial lining fluid (ELF) in a murine model of inva-
sive pulmonary aspergillosis. The posaconazole exposure (area under the plasma concentration-time curve from time zero to 24
h postinfusion [AUC0–24]) in ELF was 20% to 31% of that in plasma for total drug after the third dose, and the relationship be-
tween plasma and ELF exposure was linear (r2 0.97, P 0.016).
Inhalation of Aspergillus fumigatus conidia is the most commonroute of infection in invasive aspergillosis (IA), with the lung
being the primary site of infection. Adequate drug penetration to
the infection site is therefore crucial for optimal efficacy. Po-
saconazole is the recommended drug for prophylaxis of Aspergil-
lus diseases in neutropenic patients and stem cell transplantation
(SCT) recipients (1–3). Notably, despite relatively low levels of
free (unbound) posaconazole exposure in plasma (4–6), there ap-
pears to be an adequate protection (adequate prophylaxis) against
infection due to Aspergillus fumigatus with an MIC higher than
susceptible breakpoints to posaconazole. This is somewhat sur-
prising, compared to some other triazole antifungals in similar
animal models and clinical trials of invasive candidiasis (7). This
phenomenon could possibly be related to a higher-than-predicted
posaconazole penetration at the infection/colonization site, par-
ticularly in case of lung infection. Therefore, we set out to explore
the posaconazole concentrations and corresponding exposure in
pulmonary epithelial lining fluid (ELF) compared to those in
blood levels.
A clinical A. fumigatus isolate (posaconazole MIC of 0.5 mg/
liter) obtained from a patient with proven IA was used in the
experiments. Strain identification was confirmed by sequence-
based analysis, as described previously (8). The isolate had been
stored in 10% glycerol broth at 80°C. Before performing the
experiment, the isolate was cultured once on Sabouraud dextrose
agar (SDA) for 5 to 7 days at 35 to 37°C and subcultured twice on
15-cm Takashio slants for 5 to 7 days at 35 to 37°C. The conidia
were harvested in 20ml of sterile phosphate-buffered saline (PBS)
and 0.1% Tween 80 (Boom B.V. Meppel, the Netherlands). The
conidial suspension was filtered through sterile gauze folded four
times to remove any hyphae, and the number of conidia was
counted in a hemocytometer. After the inoculum was adjusted to
the required concentration, the conidial suspension was stored
overnight at 4°C. The in vitro antifungal susceptibility test was
performed based on the EUCAST guidelines, using a broth mi-
crodilution format (9).
A total of 96 outbred CD-1 (Charles River, the Netherlands)
female mice, 4 to 5 weeks old, weighing 20 to 22 g, were used. To
render the mice neutropenic, cyclophosphamide (150 mg/kg of
body weight on day4 and 100 mg/kg on day1) was adminis-
tered. Animals received 4, 8, 16, or 32 mg/kg posaconazole oral
solution (Schering-Plough B.V., Boxmeer, the Netherlands) once
daily at days 2, 1, and 0 by oral gavage. On day 0, mice were
infected with the A. fumigatus isolate through instillation of
conidial suspension in the nares. The infection model was con-
firmed by 0% survival in survival experimentswith untreated con-
trol animals (n  44 mice) (10, 11). Blood and bronchoalveolar
lavage (BAL) samples were drawn at 8 predefined time points
postinfection (0, 0.5, 1, 2, 4, 8, 12, and 24 h, 3 mice per each time
point), as described previously (12). Briefly, the blood samples
were drawn through the orbital vein into lithium-heparin-con-
taining tubes and were cooled and centrifuged for approximately
10 min at 1,000  g within 30 min of collection. Plasma was
aspirated, transferred in two 2-ml plastic tubes, and stored at
80°C. BAL fluid was obtained using a technique described pre-
viously (10, 11). After being sacrificed under isoflurane anesthesia
followed by cervical dislocation, themicewere secured on a plastic
platform. The trachea was exposed by a 1-cm incision on the ven-
tral neck skin for insertion of the cannula and sutured in place.
Lungs were instilled 4 times with 0.5ml of sterile 0.9% saline, with
the fluid being immediately aspirated. The aspirates recovered
from the instillations were pooled per mouse, placed on ice after
each aliquot, and subsequently stored at80°C.
Posaconazole concentrations in plasma and BAL fluid weremea-
sured by a validated (for human and mouse matrices) ultraperfor-
mance liquid chromatography (UPLC) method with fluorescence
detection.Details of the analytical assay are described elsewhere (13).
Geometric mean concentrations of total posaconazole in
plasma were calculated for each time point (n  3 mice). Peak
concentrations in plasma (Cmax) were directly observed from the
data. Pharmacokinetic parameters were derived using noncom-
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partmental analysis with Phoenix, version 6.2 (Pharsight, Inc.).
The area under the plasma concentration-time curve from time
zero to 24 h postinfusion (AUC0–24) was determined by use of the
log-linear trapezoidal rule. The elimination rate constant was de-
termined by linear regression of the terminal points of the log-
linear plasma concentration-time curve. The terminal half-life
was defined as ln2 divided by the elimination rate constant. Clear-
ance (CL) was calculated as dose/AUC0–24.
Concentrations of total posaconazole in BAL fluid from three
mice per time point were determined as described previously (13).
Urea in BAL aspirate and plasma was measured utilizing a modi-
fied enzymatic assay (QuantiChrom urea assay kit, DIUR-500;
BioAssay Systems) (14, 15). The concentration of posaconazole in
ELF was then determined by using the ratio of urea concentration
in BAL fluid to that in plasma as described previously (10, 11,
14–19): drug concentrationELF  drug concentrationBAL 
ureaplasma/ureaBAL.
All data analyses were performed using Graph-Pad Prism soft-
ware, version 5.0, for Windows (GraphPad Software, San Diego,
CA). A regression analysis was conducted to determine the linear-
ity between posaconazole concentration in blood and ELF. The
goodness of fit was checked by use of the r2 value and visual in-
spection. Statistical significance was defined as a P value of0.05
(two-tailed). The Cmax and AUC0–24 data were log10 transformed
to approximate a normal distribution prior to statistical analysis.
All animals were alive at the time of sample collection from0 to
24 h postchallenge, and 192 blood and BAL samples were ob-
tained.
The drug concentrations in plasma, including the Cmax of po-
saconazole, were higher than those in ELF for all dosages (Fig. 1).
A significant correlation between mean posaconazole concentra-
tions in plasma and ELF was noted by linear regression analysis
(r2  0.61, P  0.0001) (Fig. 2a). However, a better correlation
was found for AUC0–24 in plasma and ELF in a linear fashion for
the dosages of 4 to 32 mg/kg (r2 0.97, P 0.016) (Fig. 2b).
The total AUC0–24 in plasma and ELF is shown in Table 1. The
penetration of posaconazole in ELF based on total drug was be-
tween 20.21 and 31.39%. At the highest dose (32 mg/kg), the total
AUC0–24/MIC ratio was581 in plasma and157.56 in ELF for
the isolate with an MIC of0.5 mg/liter.
In the present study, we investigated the intrapulmonary po-
saconazole penetration in an immunosuppressed murine model
of invasive pulmonary aspergillosis receiving oral prophylactic
regimens. Our results indicate that posaconazole exposure
(AUC0–24) in ELFwas 20% to 31%of that in plasma for total drug,
and the relationship between posaconazole and AUC0–24 in
plasma and ELF was significantly linear (r2 0.97).
Our findings are comparable to the results of two clinical ob-
servations of Conte et al. (20, 21). In the first study, the plasma and
intrapulmonary concentrations of posaconazole were evaluated
in 25 healthy adult subjects receiving multiple doses (13 or 14) of
oral posaconazole suspension 400 mg twice daily with a high-fat
meal (20). The AUC0–12 values in ELF and plasma were 18.3 and
21.9mg · h/liter, respectively, corresponding to an ELF-to-plasma
penetration ratio of 86% of total drug. However, the correspond-
ing exposure in alveolar macrophages (AMs) was appreciably
higher (range, 46.2 to 87.7 mg/liter; AUC0–12 of 715 mg · h/liter).
Similarly, in the second study of the above-mentioned group (21),
FIG 1 Plasma and ELF concentrations of posaconazole following oral administration of 4, 8, 16, and 32 mg/kg to immunosuppressed mice infected with A.
fumigatus after the third dose. Each symbol corresponds to the geometric mean plasma levels for three mice.
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higher-than-predicted intrapulmonary penetration of posacona-
zole was observed in 20 adult lung transplant patients receiving
posaconazole suspension 400 mg twice daily with a high-fat meal.
The AUC0–12 values in plasma, ELF, and AMs were 10.99, 11.21,
and 530.2 mg · h/liter, respectively.
Notably, the lipophilic nature and high intracellular (cell-asso-
ciated) concentrations of posaconazole might contribute to dis-
tribution at the infection/colonization site, in this case ELF (22,
23). Campoli et al. demonstrated that lipophilic characteristics of
posaconazole increase the penetration of posaconazole intomam-
malian host cell membranes, which can mediate its efficacy in
prophylactic regimens and likely explains the observed discrep-
ancy between posaconazole low serum level and high potency
(23). They exposed intracellular cells to posaconazole and re-
moved the extracellular drug prior to infection. Epithelial cells
loadedwith posaconazole were able to inhibit fungal growth for at
least 48 h and were protected from damage caused by infection.
Cell-associated posaconazole levels were 40- to 50-fold higher
than extracellular levels, and the drugwas predominantly detected
in cellular membranes. On the other hand, Farowski et al. dem-
onstrated that administration of posaconazole oral solution re-
sulted in significantly increased intracellular concentrations in the
peripheral blood mononuclear cells (PBMCs) and polymorpho-
nuclear leukocytes (PMNs) compared to those in plasma (22).
They collected 23 blood samples from 14 patients receiving po-
saconazole for prophylaxis of fungal infections in order to deter-
mine the intracellular concentrations of posaconazole in different
compartments of the peripheral blood. These samples were sepa-
rated by double-discontinuous Ficoll-Hypaque density gradient
centrifugation. The intracellular posaconazole concentrations of
PBMCs, PMNs, and red blood cells (RBCs) were determined by
liquid chromatography-tandemmass spectrometry. The intracel-
lular concentrations of the PBMCs and PMNs were significantly
higher than those of surrounding media (P  0.001). The ratios
between the intracellular and extracellular concentrations (C/E)
were 22.5  21.2, 7.66  6.50, and 0.09  0.05 for the PBMCs,
PMNs, and RBCs, respectively.
The exposure-response relationships of posaconazole have
been defined previously in experimental models of Aspergillus in-
fections (4, 6, 24). Similar to the other triazoles, posaconazole
displays exposure-dependent pharmacodynamic characteristics,
for which a free AUC0–24/MIC ratio ranging from 1.67 to 1.78 was
the value predictive of success associated with half-maximal effi-
cacy. In general, it is accepted that only the unbound fraction of a
drug in serum/plasma is pharmacologically active. Considering
the high degree of posaconazole protein binding in plasma (98 to
99%) and negligible bounds in ELF, the results of the current
study indicated that effective local concentrations might be
achieved even at the lowest dose (4 mg/kg) with a free AUC0–24/
MIC ratio of 1.76 in plasma and 14.69 in ELF, which is probably
high enough to prevent infection with A. fumigatus isolates with
an MIC of 0.5. However, for the isolates with resistant pheno-
types and higherMIC to posaconazole (16mg/kg), the obtained
free AUC0–24/MIC in plasma was 0.18 in plasma and 4.92 in
ELF at the highest dose (32mg/kg), which indicates the possibility
of breakthrough IA.
We conclude that penetration of posaconazole in ELF is rela-
tively high, which is consistent with lipophilic characteristics and
its increased intracellular permeability. The high intrapulmonary
penetration ratio of posaconazole indicates that this agent is an
optimal therapeutic choice in prevention of IA due to azole-sus-
ceptible and/or azole-resistant A. fumigatus.
(Parts of these results were presented at the 52nd Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, 9 to 12 September 2012, and 6th Trends in Medical
Mycology, 11 to 14 October 2013, Copenhagen, Denmark.)
ACKNOWLEDGMENTS
S.S. and W.J.G.M. have no conflicts of interests. R.J.M.B., P.E.V., and
J.W.M. have served as consultants to and have received research grants
from Gilead Sciences, Merck, Astellas, and Pfizer.
FIG 2 Relationship between posaconazole concentrations (a) and AUC0–24 (b) in plasma and ELF. The line indicates the linear regression.
TABLE 1 Pharmacokinetic parameters of posaconazole in plasma and
ELF following 3 days of once daily oral administration of 4, 8, 16, and
32 mg/kg in immunosuppressed mice
Posaconazole
dose (mg/kg)
Cmax
(mg/liter)
AUC0–24
mg · h/liter
ELF-plasma
Cmax ratio
(%)
ELF-plasma
AUC0–24
ratio (%)Plasma ELF Plasma ELF
4 5.51 1.58 72.69 14.69 28.68 20.21
8 8.7 2.83 149.80 42.14 32.53 28.13
16 10.92 3.62 198.90 62.23 33.15 31.29
32 15.04 5.32 290.50 78.78 35.37 27.12
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